Overview

Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma

Status:
Terminated

Trial end date:
2005-01-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining arsenic trioxide and dexamethasone in treating patients who have recurrent or refractory stage II or stage III multiple myeloma.

Phase:

Phase 2

Details

Lead Sponsor:

CTI BioPharma

Collaborator:

National Cancer Institute (NCI)

Treatments:

Arsenic Trioxide
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate